PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34620079-11 2021 The mutation status of ERBB4 and TP53 was tightly linked to DCB of ICIs treatment, PD-L1 expression, TMB value, and TIICs. 1,2,4,5-tetramethoxybenzene 101-104 tumor protein p53 Homo sapiens 33-37 34745455-6 2021 Mutations in GATA3 and MAP3K1 in beast invasive carcinoma (BRCA), TCF7L2 in colon adenocarcinoma (COAD), NFE2L2 in esophageal carcinoma (ESCA), CIC and IDH1 in brain lower grade glioma (LGG), CDH1 in stomach adenocarcinoma (STAD), and TP53 in uterine corpus endometrial carcinoma (UCEC) were demonstrated to be correlated with lower TMB. 1,2,4,5-tetramethoxybenzene 333-336 tumor protein p53 Homo sapiens 235-239 34917611-9 2021 Compared to that in the wild type group, the TP53-mutant group showed a higher TMB value (P< 0.001), MSI value (p = 0.077), and TIDE value (p < 0.001) with respect to BC patient immunotherapy. 1,2,4,5-tetramethoxybenzene 79-82 tumor protein p53 Homo sapiens 45-49 34745095-7 2021 Moreover, TP53 mutation correlated with TMB and the immune microenvironment. 1,2,4,5-tetramethoxybenzene 40-43 tumor protein p53 Homo sapiens 10-14 34745095-9 2021 In summary, TP53 mutation is frequently mutated in AML, and its mutation is associated with dismal outcome, TMB, and immunological features, which may serve as a biomarker to predict immune response in AML. 1,2,4,5-tetramethoxybenzene 108-111 tumor protein p53 Homo sapiens 12-16 34098386-11 2021 TP53 and LRP1B mutations were significantly associated with higher TMB (both p < 0.01), which may be potential markers of immunotherapy. 1,2,4,5-tetramethoxybenzene 67-70 tumor protein p53 Homo sapiens 0-4 35280362-10 2022 A higher TMB was significantly associated with TP53-MUTs in patients with LUAD but not in those with LUSC. 1,2,4,5-tetramethoxybenzene 9-12 tumor protein p53 Homo sapiens 47-51 35601155-8 2022 TMB-related DEGs were distinctly enriched in cancer- (MAPK, P53, PI3K-Akt, and Wnt pathways) and immune-related pathways (T cell selection and differentiation). 1,2,4,5-tetramethoxybenzene 0-3 tumor protein p53 Homo sapiens 60-63 35491653-7 2022 EXPERIMENTAL DESIGN: To gain insight into the relation of the interaction of TP53 and CDKN2A mutations with TMB in HNSCC, we have analyzed genomic data from 1,669 HPV-negative HNSCC tumors with multiple criteria proposed for assessing the damaging effect of TP53 mutations. 1,2,4,5-tetramethoxybenzene 108-111 tumor protein p53 Homo sapiens 77-81 35491653-8 2022 RESULTS: Data analysis established the TP53 and CDKN2A mutation profiles in specific anatomic subsites and suggested that specific categories of TP53 mutations are more likely to associate with CDKN2A mutation or high TMB based on tumor subsite. 1,2,4,5-tetramethoxybenzene 218-221 tumor protein p53 Homo sapiens 145-149 35491653-10 2022 CONCLUSIONS: These data emphasize the role of tumor subsite in evaluation of mutational profiles in HNSCC, and link defects in TP53 and CDKN2A to elevated TMB levels in some tumor subgroups. 1,2,4,5-tetramethoxybenzene 155-158 tumor protein p53 Homo sapiens 127-131 35344507-6 2022 However, the genotype of TP53MUTBRAFWT in high-TMB status cohort have poorer response to ICI therapy than the genotype of BRAFMUTTP53WT in low-TMB status (Median, 18 months vs 47 month). 1,2,4,5-tetramethoxybenzene 47-50 tumor protein p53 Homo sapiens 25-29 35368662-12 2022 Further analysis showed that LGG patients with TP53 R273C mutation had higher M2 macrophage infiltration and tumor mutation burden (TMB) than that of TP53 wild-type LGG patients, and higher TMB indicates poor prognosis in LGG patients. 1,2,4,5-tetramethoxybenzene 132-135 tumor protein p53 Homo sapiens 47-51 35368662-12 2022 Further analysis showed that LGG patients with TP53 R273C mutation had higher M2 macrophage infiltration and tumor mutation burden (TMB) than that of TP53 wild-type LGG patients, and higher TMB indicates poor prognosis in LGG patients. 1,2,4,5-tetramethoxybenzene 190-193 tumor protein p53 Homo sapiens 47-51 35368662-13 2022 Furthermore, we identified genes which could be associated with higher M2 macrophage infiltration and TMB in LGG patients with TP53 R273C mutation. 1,2,4,5-tetramethoxybenzene 102-105 tumor protein p53 Homo sapiens 127-131 35280362-13 2022 Conclusions: In contrast to most previous studies, we revealed TP53-MUT characteristic in NSCLC patients according to histology-specific differences and the association between TP53-MUT and the mutation landscape, the TMB, and the OS. 1,2,4,5-tetramethoxybenzene 218-221 tumor protein p53 Homo sapiens 63-67 35242380-13 2022 The TMB value was significantly higher in those with P53 mutation than in P53 wild-type patients. 1,2,4,5-tetramethoxybenzene 4-7 tumor protein p53 Homo sapiens 53-56 35111281-6 2022 TMB was associated with ALK (p = 0.01), EGFR (p < 0.01), and TP53 (p < 0.05) alterations. 1,2,4,5-tetramethoxybenzene 0-3 tumor protein p53 Homo sapiens 61-65 35242380-13 2022 The TMB value was significantly higher in those with P53 mutation than in P53 wild-type patients. 1,2,4,5-tetramethoxybenzene 4-7 tumor protein p53 Homo sapiens 74-77 33879103-7 2021 RESULTS: Samples with co-altered RB1&TP53: a) were enriched in immunity effectors (CD8 cytotoxic lymphocytes, NK cells) and display higher scores of a T cell inflamed signature; b) have a higher TMB, higher number of SNV predicted neoantigens and higher TILs fractions; c) have a higher number of DDR mutated and deep deleted DDR genes; d) have DNA somatic signatures 2 and 13 related to APOBEC mutagenesis. 1,2,4,5-tetramethoxybenzene 195-198 tumor protein p53 Homo sapiens 33-41 33996530-9 2020 TP53 mutations also influence TMB distribution (P < 0.001). 1,2,4,5-tetramethoxybenzene 30-33 tumor protein p53 Homo sapiens 0-4 33879103-8 2021 Using the IMVigor 210 dataset, RB1&TP53 samples had the highest response rate to atezolizumab and a strong correlation with TMB and TMM. 1,2,4,5-tetramethoxybenzene 124-127 tumor protein p53 Homo sapiens 31-39 33454519-9 2021 The median TMB was higher in TP53-mutant tumors than in wild-type tumors (10.1 versus 7.2 mutations/Mb, p = 0.019). 1,2,4,5-tetramethoxybenzene 11-14 tumor protein p53 Homo sapiens 29-33 33987249-13 2021 Moreover, many top gene set enrichment analysis (GSEA) results, including amino sugar and nucleotide sugar metabolism, nucleotide excision repair, or p53 signaling pathway, were enriched significantly with TMB level as phenotype. 1,2,4,5-tetramethoxybenzene 206-209 tumor protein p53 Homo sapiens 150-153 33363171-11 2020 Although TP53-MT was associated with a high TMB, the expression of most immune checkpoint molecules and immune-related genes was lower in TP53-MT patients than TP53-WT patients, which may reflect low immunogenicity. 1,2,4,5-tetramethoxybenzene 44-47 tumor protein p53 Homo sapiens 9-13 33391418-9 2021 And TP53 mutations were also associated with higher TMB in the TCGA and Chinese cohort (P = 0.0005 and 0.0010, respectively). 1,2,4,5-tetramethoxybenzene 52-55 tumor protein p53 Homo sapiens 4-8 33391418-12 2021 Conclusions: The results suggest that LRP1B or TP53 mutations are associated with higher TMB and a poor prognostic factor in HCC. 1,2,4,5-tetramethoxybenzene 89-92 tumor protein p53 Homo sapiens 47-51 31173964-7 2019 TMB was correlated with TP53 genotype, human papilloma virus (HPV) status, immune expression signatures and survival parameters. 1,2,4,5-tetramethoxybenzene 0-3 tumor protein p53 Homo sapiens 24-28 33219256-9 2020 TMB-associated mutations included CDKN2A, LRP1B, LRP2, TP53, and EGFR. 1,2,4,5-tetramethoxybenzene 0-3 tumor protein p53 Homo sapiens 55-59 32927274-8 2020 On the other-side, both TP53 missense and nonsense mutations are associated with elevated TMB and neoantigen levels and contribute equally to DNA damage repair deficiency. 1,2,4,5-tetramethoxybenzene 90-93 tumor protein p53 Homo sapiens 24-28 31596511-7 2020 Pathway analysis suggested that differential TMB-related signature correlated with multiple cancer-related crosstalk, including cell cycle, DNA replication, cellular senescence, and p53 signaling pathway. 1,2,4,5-tetramethoxybenzene 45-48 tumor protein p53 Homo sapiens 182-185 32218826-6 2020 Further analysis using The Cancer Genome Atlas Liver Hepatocellular Carcinoma database showed that TP53, CTNNB1 and MLL mutations were positively correlated with TMB-H. 1,2,4,5-tetramethoxybenzene 162-165 tumor protein p53 Homo sapiens 99-103 31807880-9 2020 TMB was significantly higher in men, current or former smokers, and in patients with squamous cell carcinoma, tumor size >= 2.8 cm, wild-type EGFR, TP53 gene mutation-positive status, and cyclin-dependent kinase-inhibitor gene 2A mutation-positive status. 1,2,4,5-tetramethoxybenzene 0-3 tumor protein p53 Homo sapiens 148-152 31807880-10 2020 According to multivariate analysis, TMB was significantly associated with EGFR gene mutation-negative status (p = 0.0111) and TP53 gene mutation-positive status (p = 0.0425). 1,2,4,5-tetramethoxybenzene 36-39 tumor protein p53 Homo sapiens 126-130 32743759-14 2020 OS in the high TMB cohort was significantly better than that in the low TMB in patients with TP53 MUT(43.2 m vs 32.4 m; P = 0.007, HR = 0.52, 95% CI: 0.34-0.81), as well as in the combination of TP53 MUT and EGFR WT group (44.4 m vs 31.2 m; P = 0.021, HR = 0.55, 95% CI 0.34 - 0.89). 1,2,4,5-tetramethoxybenzene 15-18 tumor protein p53 Homo sapiens 195-199 32743759-14 2020 OS in the high TMB cohort was significantly better than that in the low TMB in patients with TP53 MUT(43.2 m vs 32.4 m; P = 0.007, HR = 0.52, 95% CI: 0.34-0.81), as well as in the combination of TP53 MUT and EGFR WT group (44.4 m vs 31.2 m; P = 0.021, HR = 0.55, 95% CI 0.34 - 0.89). 1,2,4,5-tetramethoxybenzene 72-75 tumor protein p53 Homo sapiens 93-97 33178836-14 2020 The TMB and mutations of KRAS, EGFR, STK11, and TP53 were correlated with GNPNAT1. 1,2,4,5-tetramethoxybenzene 4-7 tumor protein p53 Homo sapiens 48-52 33072585-5 2020 Results: KRAS mutation with concurrent TP53 or STK11 mutations had higher TMB and CNA compared to KRAS mutation alone. 1,2,4,5-tetramethoxybenzene 74-77 tumor protein p53 Homo sapiens 39-43 33072585-6 2020 The KRAS G12C and G > T mutation subgroups, with TP53 or STK11 co-mutation, also had higher TMB and CNA. 1,2,4,5-tetramethoxybenzene 92-95 tumor protein p53 Homo sapiens 49-53 32739866-9 2020 Finally, TP53 mutations are associated with higher TMB score in metastatic but not primary tumors, and poorer response to immune checkpoint inhibitors for the latter. 1,2,4,5-tetramethoxybenzene 51-54 tumor protein p53 Homo sapiens 9-13 32694238-7 2020 These findings demonstrate that truncating TP53 mutations correlate with poor immunotherapy outcomes in NSCLC patients with low TMB. 1,2,4,5-tetramethoxybenzene 128-131 tumor protein p53 Homo sapiens 43-47 31173964-10 2019 High TMB was significantly associated with an increased prevalence of TP53 mutations and immune gene expression patterns unrelated to T cell-inflamed gene expression profiles. 1,2,4,5-tetramethoxybenzene 5-8 tumor protein p53 Homo sapiens 70-74 31164161-7 2019 High tumor mutation burden (TMB) gathered in TP53 wild-type tumors (p = 0.045). 1,2,4,5-tetramethoxybenzene 28-31 tumor protein p53 Homo sapiens 45-49 31097096-2 2019 We hypothesized that TP53 mutations could reflect TMB and be associated with ICI benefit. 1,2,4,5-tetramethoxybenzene 50-53 tumor protein p53 Homo sapiens 21-25 28892622-6 2017 As Au-NPFe2O3NC possess high peroxidase-like activity for the oxidation of TMB in the presence of H2O2 [TMB is a common chromogenic substrate for HRP in enzyme-linked immunosorbent assays (ELISAs)], we envisage that our assay could find a wide range of application in developing ELISA-based sensing approaches in the fields of medicine (i.e., detection of other biomarkers the same as p53 autoantibody), biotechnology, and environmental sciences. 1,2,4,5-tetramethoxybenzene 75-78 tumor protein p53 Homo sapiens 385-388 28892622-6 2017 As Au-NPFe2O3NC possess high peroxidase-like activity for the oxidation of TMB in the presence of H2O2 [TMB is a common chromogenic substrate for HRP in enzyme-linked immunosorbent assays (ELISAs)], we envisage that our assay could find a wide range of application in developing ELISA-based sensing approaches in the fields of medicine (i.e., detection of other biomarkers the same as p53 autoantibody), biotechnology, and environmental sciences. 1,2,4,5-tetramethoxybenzene 104-107 tumor protein p53 Homo sapiens 385-388